Data and Code for: The Anticompetitive Effects of Common Ownership: The Case of Paragraph IV Generic Entry

Principal Investigator(s):  View help for Principal Investigator(s) Jin Xie, The Chinese University of Hong Kong

Version:  View help for Version V1

Name File Type Size Last Modified
Code.txt text/plain 2.2 KB 10/12/2020 09:35:AM
DATA.dta application/x-stata 253 KB 08/24/2020 12:46:PM
README.txt text/plain 135 bytes 08/24/2020 12:43:PM

Project Citation: 

Xie, Jin. Data and Code for: The Anticompetitive Effects of Common Ownership: The Case of Paragraph IV Generic Entry. Nashville, TN: American Economic Association [publisher], 2020. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2020-10-12. https://doi.org/10.3886/E120742V1

Project Description

Summary:  View help for Summary Brand-name pharmaceutical companies often file lawsuits against generic drug manufacturers that challenge the monopoly status of patent-protected drugs. Institutional horizontal shareholdings, measured by the generic shareholders' ownership in the brand-name company relative to their ownership in the generic manufacturer, are significantly positively associated with the likelihood that the two parties enter into a settlement agreement in which the brand pays the generic manufacturer to stay out of the market.
Funding Sources:  View help for Funding Sources Hong Kong Research Grants Council. General Research Fund (14507416)

Scope of Project

Subject Terms:  View help for Subject Terms Common ownership; Settlement agreement; Pharmaceutical industry; Patent infringement lawsuit; Antitrust
JEL Classification:  View help for JEL Classification
      G23 Pension Funds; Non-bank Financial Institutions; Financial Instruments; Institutional Investors
      G30 Corporate Finance and Governance: General
      L12 Monopoly; Monopolization Strategies
      L41 Monopolization; Horizontal Anticompetitive Practices
Geographic Coverage:  View help for Geographic Coverage United States
Time Period(s):  View help for Time Period(s) 11/1/2003 – 8/30/2017
Collection Date(s):  View help for Collection Date(s) 7/1/2015 – 10/31/2019
Universe:  View help for Universe Pharmaceutical firms in the United States, 2003-2017
Institutional Investors in the United States, 2000-2017
Data Type(s):  View help for Data Type(s) administrative records data

Methodology

Sampling:  View help for Sampling Our data come from The Paragraph Four Report, which is an electronic publication of Parry Ashford Inc. The company tracks and analyzes Paragraph~IV activities. The database starts with Paragraph~IV cases that were active as of November 1, 2003. Active branded products are those that had a Paragraph~IV challenge, had a pending lawsuit, and were not available as a generic as of November 1, 2003. The company followed each case through completion (i.e., settlement or court of appeals). Once a generic product enters the market after final termination of litigation, the product is removed from the list and sent to the Old Cases section. The Old Cases section includes products and cases closed after November 1, 2003.
Data Source:  View help for Data Source The Paragraph Four Report, which is an electronic publication of Parry Ashford Inc.
Collection Mode(s):  View help for Collection Mode(s) other; web scraping
Unit(s) of Observation:  View help for Unit(s) of Observation Paragraph IV Lawsuit
Geographic Unit:  View help for Geographic Unit Lawsuit

Related Publications

Download this project

Published Versions

V1 [2020-10-12]

Export Metadata

Dublin Core

DDI 2.5

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.